Brain-Computer Interface for ALS
What You Need to Know Before You Apply
What is the purpose of this trial?
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.
As ALS progresses, speech is lost and many people come to rely on an eye-tracking speech generating device. Eye-tracking performance can decline as oculomotor control is affected, and some people reach a point where it no longer works reliably for them. The Cognixion ONE device adds a brain-computer interface input, which does not depend on eye movement, alongside an AI-assisted communication application.
Thirty adults with ALS who currently use a Tobii Dynavox or Smartbox eye-tracking device will take part. Each participant uses three communication options at home over a 12-week period: their own eye-tracking device, the Cognixion ONE device with a head-worn augmented-reality display, and the Cognixion ONE device with a screen-based display. For some sessions the option is assigned; for others the participant chooses.
The main measure is how much time participants voluntarily choose to spend using each option. That choice is treated as the clearest signal of which option genuinely works better for them. The study also measures communication speed and accuracy, usability, workload, quality of life, and caregiver burden.
The Cognixion ONE device is an investigational research device. It is not approved or cleared by the U.S. Food and Drug Administration for any medical use.
Who Is on the Research Team?
Chris Ullrich, M.Sc.
Principal Investigator
Cognixion Corporation
Are You a Good Fit for This Trial?
This trial is for adults with ALS who currently use an eye-tracking speech device (like Tobii Dynavox or Smartbox) to communicate. Participants must be able to try new communication devices at home over a 12-week period.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Cognixion ONE AR-BCI configuration
- Cognixion ONE screen-based BCI configuration
Trial Overview
The study compares three ways for people with ALS to communicate: their usual eye-tracking device, the Cognixion ONE brain-computer interface (BCI) headset, and a screen-based version of Cognixion ONE. Each participant tries all options at home.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Axon-R EEG assembly with an external screen display running the same Assisted Reality communication application. No head-worn display is used.
Axon-R EEG assembly with a head-worn augmented-reality display (Apple Vision Pro or XReal AR glasses, selected per participant) running the Assisted Reality communication application.
The participant's own commercial eye-gaze speech generating device (Tobii Dynavox or Smartbox Grid Pad with eye-gaze module), used in matched-task and free-conversation sessions throughout the window.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cognixion
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.